← back to search

Konstantin Penkov

City Clinical Hospital No 31 ·
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, and Renal cell carcinoma treatment.
h-index
18
citations
4,252
works
53
NIH funding
primary concept
Medicine
email

Recent publications

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
Annals of Oncology 2024cited by 45position: middledoi
Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
Journal of Clinical Oncology 2024cited by 26position: middledoi
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations
Journal of Thoracic Oncology 2023cited by 50position: middledoi
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
Journal of Thoracic Oncology 2021cited by 248position: middledoi
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
Clinical Cancer Research 2021cited by 75position: middledoi
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Nature Medicine 2020cited by 515position: middledoi
PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC).
Journal of Clinical Oncology 2020cited by 19position: lastdoi
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
New England Journal of Medicine 2019cited by 2,524position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Sumanta K. Pal · City of Hope2 papers (2020–2020)Toni K. Choueiri · Harvard University2 papers (2020–2024)Robert J. Motzer · Texas Oncology2 papers (2020–2024)Jae‐Lyun Lee · Ulsan College2 papers (2020–2024)Harry J.M. Groen · University Medical Center Groningen2 papers (2021–2021)Laurence Albigès · Institut Gustave Roussy2 papers (2020–2024)James Larkin · Trinity College Dublin2 papers (2020–2024)Alessandra di Pietro · Pfizer (Italy)2 papers (2020–2024)Matthew T. Campbell · The University of Texas MD Anderson Cancer Center2 papers (2020–2024)John B.A.G. Haanen · Nikki-Universal (Japan)2 papers (2020–2024)Patricia M. de Groot · The University of Texas MD Anderson Cancer Center1 papers (2021–2021)B. Yа. Alekseev · Ministry of Health1 papers (2020–2020)Daniel J. George · Université de Strasbourg1 papers (2020–2020)Sylvie Négrier · Université Claude Bernard Lyon 11 papers (2024–2024)Keith A. Ching · Pfizer (United States)1 papers (2020–2020)Brian I. Rini · Cancer Research UK1 papers (2024–2024)Kingston Kang · AbbVie (United States)1 papers (2021–2021)Alessandra Bearz · National Cancer Institute1 papers (2023–2023)L. Caffrey · AbbVie (United States)1 papers (2021–2021)Philip Komarnitsky · AbbVie (United States)1 papers (2021–2021)